New Advances in Using Virus-like Particles and Related Technologies for Eukaryotic Genome Editing Delivery

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 12

PMID 35955895

Authors

Pin Lyu

Baisong Lu

Affiliations

Soon will be listed here.

Abstract

The designer nucleases, including Zinc Finger Nuclease (ZFN), Transcription Activator-Like Effector Nuclease (TALEN), and Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated (CRISPR/Cas), have been widely used for mechanistic studies, animal model generation, and gene therapy development. Clinical trials using designer nucleases to treat genetic diseases or cancers are showing promising results. Despite rapid progress, potential off-targets and host immune responses are challenges to be addressed for in vivo uses, especially in clinical applications. Short-term expression of the designer nucleases is necessary to reduce both risks. Currently, delivery methods enabling transient expression of designer nucleases are being pursued. Among these, virus-like particles as delivery vehicles for short-term designer nuclease expression have received much attention. This review will summarize recent developments in using virus-like particles (VLPs) for safe delivery of gene editing effectors to complement our last review on the same topic. First, we introduce some background information on how VLPs can be used for safe and efficient CRISPR/Cas9 delivery. Then, we summarize recently developed virus-like particles as genome editing vehicles. Finally, we discuss applications and future directions.

Citing Articles

Advances in RNA-Based Therapeutics: Challenges and Innovations in RNA Delivery Systems.

Liu Y, Ou Y, Hou L Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852137 PMC: 11763986. DOI: 10.3390/cimb47010022.

Significance of VLPs in Vlp-circRNA vaccines: a vaccine candidate or delivery vehicle?.

Gupta R, Arora K, Mehrotra Arora N, Kundu P RNA Biol. 2024; 21(1):17-28.

PMID: 39240021 PMC: 11382717. DOI: 10.1080/15476286.2024.2399307.

Emerging trends in virus and virus-like particle gene therapy delivery to the brain.

Mandalawatta H, Rajendra K, Fairfax K, Hewitt A Mol Ther Nucleic Acids. 2024; 35(3):102280.

PMID: 39206077 PMC: 11350507. DOI: 10.1016/j.omtn.2024.102280.

References

Zhang Z, Jimenez-Bonilla P, Seo S, Lu T, Jin Y, Blaschek H . Bacterial Genome Editing with CRISPR-Cas9: Taking Clostridium beijerinckii as an Example. Methods Mol Biol. 2018; 1772:297-325. DOI: 10.1007/978-1-4939-7795-6_17. View

Tabebordbar M, Zhu K, Cheng J, Chew W, Widrick J, Yan W . In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016; 351(6271):407-411. PMC: 4924477. DOI: 10.1126/science.aad5177. View

Lindel F, Dodt C, Weidner N, Noll M, Bergemann F, Behrendt R . TraFo-CRISPR: Enhanced Genome Engineering by Transient Foamy Virus Vector-Mediated Delivery of CRISPR/Cas9 Components. Mol Ther Nucleic Acids. 2019; 18:708-726. PMC: 6859288. DOI: 10.1016/j.omtn.2019.10.006. View

Mock U, Riecken K, Berdien B, Qasim W, Chan E, Cathomen T . Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Sci Rep. 2014; 4:6409. PMC: 4166709. DOI: 10.1038/srep06409. View

Rees H, Komor A, Yeh W, Caetano-Lopes J, Warman M, Edge A . Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat Commun. 2017; 8:15790. PMC: 5467206. DOI: 10.1038/ncomms15790. View

Escola J, Kleijmeer M, Stoorvogel W, Griffith J, Yoshie O, Geuze H . Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 1998; 273(32):20121-7. DOI: 10.1074/jbc.273.32.20121. View

Joo K, Wang P . Visualization of targeted transduction by engineered lentiviral vectors. Gene Ther. 2008; 15(20):1384-96. PMC: 2575058. DOI: 10.1038/gt.2008.87. View

Mali P, Aach J, Stranges P, Esvelt K, Moosburner M, Kosuri S . CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8. PMC: 3818127. DOI: 10.1038/nbt.2675. View

Knopp Y, Geis F, Heckl D, Horn S, Neumann T, Kuehle J . Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout. Mol Ther Nucleic Acids. 2018; 13:256-274. PMC: 6187057. DOI: 10.1016/j.omtn.2018.09.006. View

10.

Nelson C, Wu Y, Gemberling M, Oliver M, Waller M, Bohning J . Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019; 25(3):427-432. PMC: 6455975. DOI: 10.1038/s41591-019-0344-3. View

11.

Baron Y, Sens J, Lange L, Nassauer L, Klatt D, Hoffmann D . Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells. Mol Ther Nucleic Acids. 2022; 27:810-823. PMC: 8801357. DOI: 10.1016/j.omtn.2021.12.033. View

12.

Hamilton J, Tsuchida C, Nguyen D, Shy B, McGarrigle E, Sandoval Espinoza C . Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 2021; 35(9):109207. PMC: 8236216. DOI: 10.1016/j.celrep.2021.109207. View

13.

Cradick T, Fine E, Antico C, Bao G . CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013; 41(20):9584-92. PMC: 3814385. DOI: 10.1093/nar/gkt714. View

14.

Kallimasioti-Pazi E, Thelakkad Chathoth K, Taylor G, Meynert A, Ballinger T, Kelder M . Heterochromatin delays CRISPR-Cas9 mutagenesis but does not influence the outcome of mutagenic DNA repair. PLoS Biol. 2018; 16(12):e2005595. PMC: 6306241. DOI: 10.1371/journal.pbio.2005595. View

15.

Choi J, Dang Y, Abraham S, Ma H, Zhang J, Guo H . Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 2016; 23(7):627-33. DOI: 10.1038/gt.2016.27. View

16.

Wulczyn F, Kahmann R . Translational stimulation: RNA sequence and structure requirements for binding of Com protein. Cell. 1991; 65(2):259-69. DOI: 10.1016/0092-8674(91)90160-z. View

17.

Gutierrez-Guerrero A, Abrey Recalde M, Mangeot P, Costa C, Bernadin O, Perian S . Baboon Envelope Pseudotyped "Nanoblades" Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34 Cells and Knock-in of AAV6-Encoded Donor DNA in CD34 Cells. Front Genome Ed. 2021; 3:604371. PMC: 8525375. DOI: 10.3389/fgeed.2021.604371. View

18.

Yin D, Ling S, Wang D, Dai Y, Jiang H, Zhou X . Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat Biotechnol. 2021; 39(5):567-577. PMC: 7611178. DOI: 10.1038/s41587-020-00781-8. View

19.

Indikova I, Indik S . Highly efficient 'hit-and-run' genome editing with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts. Nucleic Acids Res. 2020; 48(14):8178-8187. PMC: 7430633. DOI: 10.1093/nar/gkaa561. View

20.

Lyu P, Yoo K, Yadav M, Atala A, Aartsma-Rus A, van Putten M . Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay. PLoS One. 2020; 15(9):e0239468. PMC: 7514106. DOI: 10.1371/journal.pone.0239468. View